BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Rai V, Mukherjee S. Targets of immunotherapy for hepatocellular carcinoma: An update. World J Hepatol 2022; 14(1): 140-157 [DOI: 10.4254/wjh.v14.i1.140] [Reference Citation Analysis]
2 Yang YL, Tsai MC, Chang YH, Wang CC, Chu PY, Lin HY, Huang YH. MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA. Int J Mol Sci 2021;22:6001. [PMID: 34206143 DOI: 10.3390/ijms22116001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers (Basel) 2021;13:514. [PMID: 33572780 DOI: 10.3390/cancers13030514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
4 Hassan M, Nasr SM, Elzallat M. Effect of CD133 Polymorphisms on the Risk of Developing Liver Cirrhosis and hepatocellular carcinoma Induced by Viral Hepatitis. Virus Res 2022;:198714. [PMID: 35181408 DOI: 10.1016/j.virusres.2022.198714] [Reference Citation Analysis]
5 Aly A, Lingohr-Smith M, Lin J, Seal B. Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA. Hepat Oncol 2021;8:HEP37. [PMID: 34408847 DOI: 10.2217/hep-2021-0001] [Reference Citation Analysis]
6 Zheng Y, Zhang X, Lu J, Liu S, Qian Y. Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Med 2021;10:7347-59. [PMID: 34414679 DOI: 10.1002/cam4.4223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lal LS, Aly A, Le LB, Peckous S, Seal B, Teitelbaum A. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. Cancer Rep (Hoboken) 2021;:e1504. [PMID: 34494389 DOI: 10.1002/cnr2.1504] [Reference Citation Analysis]
8 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacol Res 2022;181:106261. [PMID: 35588918 DOI: 10.1016/j.phrs.2022.106261] [Reference Citation Analysis]
9 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Reference Citation Analysis]
10 Verma M, Paik JM, Younossi I, Tan D, Abdelaal H, Younossi ZM. The impact of hepatocellular carcinoma diagnosis on patients' health-related quality of life. Cancer Med 2021;10:6273-81. [PMID: 34405568 DOI: 10.1002/cam4.4166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Arif D, Mettler T, Adeyi OA. Mimics of hepatocellular carcinoma: a review and an approach to avoiding histopathological diagnostic missteps. Hum Pathol 2021;112:116-27. [PMID: 33346018 DOI: 10.1016/j.humpath.2020.12.002] [Reference Citation Analysis]
12 Zheng T, Zhang X, Wang Y, Wang A. SPOCD1 regulated by miR-133a-3p promotes hepatocellular carcinoma invasion and metastasis. J Int Med Res 2022;50:030006052110537. [DOI: 10.1177/03000605211053717] [Reference Citation Analysis]
13 Evangelista J, Zaninotto E, Gaglio A, Ghidini M, Raimondi L. MicroRNAs as Diagnostic Tools in Hepatocellular Carcinoma. GastrointestDisord 2021;3:237-46. [DOI: 10.3390/gidisord3040022] [Reference Citation Analysis]
14 Ronnebaum S, Aly A, Patel D, Benavente F, Rueda JD. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepat Oncol 2022;9:HEP41. [PMID: 34765109 DOI: 10.2217/hep-2021-0003] [Reference Citation Analysis]
15 Yang YL, Chang YH, Li CJ, Huang YH, Tsai MC, Chu PY, Lin HY. New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics. J Pers Med 2021;11:219. [PMID: 33803804 DOI: 10.3390/jpm11030219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]